Ultimovacs ASA reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was NOK 189.24 million compared to NOK 167.79 million a year ago. Basic loss per share from continuing operations was NOK 5.5 compared to NOK 4.9 a year ago.
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
7.03 NOK | 0.00% | +0.72% | -94.28% |
07/05 | Transcript : Ultimovacs ASA, Q1 2024 Earnings Call, May 07, 2024 | |
17/04 | Ultimovacs to Reduce 40% of Workforce Amid Operational Adjustments | MT |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-94.28% | 22.18M | |
+22.56% | 46.71B | |
-1.51% | 41.52B | |
+48.83% | 41.8B | |
-3.42% | 29.55B | |
+10.13% | 25.78B | |
-20.44% | 19.26B | |
+26.45% | 11.98B | |
-0.14% | 12.14B | |
-0.47% | 12.08B |
- Stock Market
- Equities
- ULTI Stock
- News Ultimovacs ASA
- Ultimovacs ASA Reports Earnings Results for the Full Year Ended December 31, 2023